For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230228:nRSb2203Ra&default-theme=true
RNS Number : 2203R Benchmark Holdings PLC 28 February 2023
28 February 2023
Information within this announcement is deemed by the Company to constitute
inside information under the Market Abuse Regulations (EU) No. 596/2014
Benchmark Holdings plc
("Benchmark", the "Company" or the "Group")
Q1 Results
(Three months ended 31 December 2022)
Excellent start to the year with growth in all business areas and
significant uplift in Health
In compliance with the terms of the Company's unsecured Green bond, which
requires it to publish quarterly financial information, Benchmark, the
aquaculture biotechnology business, announces its unaudited results for the
three months ended 31 December 2022 (the "Period"), which constitute the first
quarter for the fiscal year ("FY") 2023. All Q1 FY22 and Q1 FY23 figures
quoted in this announcement are based on unaudited accounts.
Financial highlights
Continuation of consistent year-on-year growth in Revenue and Adjusted EBITDA
on a rolling twelve month basis
· Q1 FY23 revenues were £54.5m, 36% ahead of the prior year (+29% CER)
o Genetics delivered strong revenue growth 41% above Q1 FY22, driven
primarily by higher sales of salmon eggs and harvest revenues
o Advanced Nutrition also reported strong growth with revenues 19% above Q1
FY22, benefitting from continued positive trading and forex movements
o Health reported excellent growth with revenues 80% above Q1 FY22, driven
by increased adoption of Ectosan® Vet and CleanTreat® and significantly
higher sales of Salmosan® Vet
· Q1 FY23 Adjusted EBITDA excluding fair value movements from
biological assets increased 61% (+56% CER) to £12.1m as a result of higher
revenues, higher asset utilisation and continued cost discipline
o Notably, Adjusted EBITDA in Health increased substantially to £4.1m in
the quarter (Q1 FY22: £0.5m) demonstrating the potential of this business
area to deliver good profitability
o Group Adjusted EBITDA margin of 22% excluding fair value movements from
biological assets (Q1 FY22:19%)
· Net operating loss of £0.1m (Q1 FY22: £1.5m loss)
· Net loss of -£0.7m significantly reduced from prior year (Q1 FY22:
-£5.1m)
· Cash inflow from operating activities of £8.1m (Q1 FY22: inflow
£1.1m)
· Cash, liquidity and net debt all improved compared to the year end
position:
o Cash of £42.8m and liquidity of £62.8m (cash and available facility)
o Reduced net debt excluding lease liabilities of £37.9m (30 September
2022: £47.5m)
o Includes benefit of net proceeds from the fundraise in December 2022 of
£11.6m
Operational highlights
· Advanced Nutrition - continued good performance despite relative
softness in the shrimp market
o Growth in all product areas
o Adjusted EBITDA margin in line with prior year at 23% (Q1 FY22: 23%)
benefitting from success of new commercial focus, cost discipline and ongoing
actions to improve efficiency and asset utilisation offsetting cost inflation
o Continued innovation with pre-launch of new artemia tool which counts
hatched Artemia
· Genetics - Continued growth in salmon egg sales with record number of
eggs sold
o 118m eggs sold in Q1 FY23 (Q1 FY22: 76m eggs) demonstrating continued
success in meeting increased customer demand supported by recent investment in
incubation unit in Iceland
o Temporary slowdown in commercialisation of shrimp genetics (SPR shrimp) in
order to refine product offering based on customer feedback from first
commercial cycle. Expect to relaunch commercial effort in H2
o Post period end, acquisition of remaining 10.52% minority interest in its
subsidiary Benchmark Genetics Iceland, ensuring Benchmark receives the full
benefit from its successful salmon genetics business in Iceland which
represents 50% of the Group's salmon egg capacity
o Exploring strategic alternatives for tilapia breeding activities
· Health - Significant increase in customer adoption of Ectosan® Vet
and CleanTreat®
o Significant growth in customer adoption of Ectosan® Vet and CleanTreat®
with repeat orders and new client wins which resulted in improved capacity
utilisation and strong profitability
o Progress made towards development of new business model for Ectosan® Vet
and CleanTreat® aimed at reducing infrastructure costs and capex
§ Timing of commercial launch of integrated wellboat projects subject to
availability and adoption of new large wellboats by customers
§ Progress being made around Customer owned PSV's which represent a viable
alternative in the medium to long term
Oslo Børs listing
§ Progress towards listing on the Oslo Børs, the leading seafood and
aquaculture listing venue globally; ongoing shareholder consultation on
whether to maintain an AIM listing
Current trading and outlook
· Strong Q1 FY23 performance and continued positive trading post period
end. Encouraging outlook for the full year
o Genetics - good visibility of revenues
o Advanced Nutrition - continuing positive performance despite some softness
in the shrimp market
o Health - increasing evidence of customer growing adoption of Ectosan® Vet
and CleanTreat®
Financial Summary
£m Q1 FY23 Q1 FY22 % AER % CER(**) FY22
(full year)
Revenue 54.5 40.0 +36% +29% 158.3
Adjusted
Adjusted EBITDA(1) 11.0 7.4 +48% +44% 31.2
Adj. EBITDA excluding fair value movement in biological asset 12.1 7.5 +61% +56% 29.6
Adjusted Operating Profit(2) 5.7 2.5 +131% +127% 9.1
Statutory
Operating loss (0.1) (1.5) +92% +86% (7.9)
Profit/(loss) before tax 0.1 (3.7) +103% +114% (23.2)
Loss for the period (0.7) (5.1) +87% +96% (30.5)
Basic loss per share (p) (0.18) (0.79) (4.60)
Net debt(3) (61.4) (64.3) (73.7)
Net debt excluding lease liabilities (37.9) (43.1) (47.5)
Business Area summary
£m Q1 FY23 Q1 FY22 % AER % CER(**) FY22
(full year)
Revenue
Advanced Nutrition 22.7 19.1 +19% +4% 80.3
Genetics 21.4 15.2 +41% +42% 58.0
Health 10.4 5.8 +80% +80% 20.1
Adjusted EBITDA(1)
Advanced Nutrition 5.3 4.3 +23% +9% 19.0
Genetics 2.6 3.3 -21% -10% 16.0
- Genetics net of fair value movements in biological assets 3.7 3.4 +11% +19% 14.4
Health 4.1 0.5 +643% +635% 0.1
*Constant exchange rate (CER) figures derived by retranslating current year
figures using previous year's foreign exchange rates
(1) Adjusted EBITDA is EBITDA (earnings before interest, tax, depreciation and
amortisation and impairment), before exceptional items
(2) Adjusted Operating Profit is operating gain or loss before exceptional
items and amortisation of intangible assets excluding development costs
(3) Net debt is cash and cash equivalents less loans and borrowings
Trond Williksen, CEO, commented:
"Benchmark has had an excellent start to the year, again showing a
continuation of the consistent growth we have seen in revenues and net
operating profit on a twelve month rolling basis. This is the result of a good
performance in all our business areas. In particular, it is pleasing to see
traction in our Health business driven by significantly higher adoption of our
sea lice solutions, contributing to a positive financial performance for the
quarter."
"We are making progress towards our goal of up-listing to the Oslo Børs, the
preeminent listing venue for aquaculture and seafood companies globally. This
will enable us to increase our visibility with a dedicated group of analysts
and investors."
"We are grateful to our existing shareholders for their support through the
years and we are committed to continuing to deliver improved financial
performance and strategic progress for the benefit of all our stakeholders."
Analyst / investor presentation and webcast being held today
Trond Williksen, Chief Executive Officer and Septima Maguire, Chief Financial
Officer will host an in-person presentation for analysts and institutional
investors today at 9.00 am CET/8.00 am UK time. The presentation will take
place at Hotel Continental, Stortingsgata 24/26, 0117 Oslo.
A live webcast of the presentation is available for analysts and investors to
join remotely at the following link:
https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230228_7
(https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20230228_7)
Enquiries
For further information, please contact:
Benchmark Holdings plc benchmark@mhpgroup.com
Trond Williksen, CEO
Septima Maguire, CFO
Ivonne Cantu, Investor Relations
Numis (Broker and NOMAD) Tel: +44(0) 20 7260 1000
James Black, Freddie Barnfield, Duncan Monteith
MHP Tel: +44(0) 20 3128 8004
Katie Hunt, Reg Hoare, Veronica Farah benchmark@mhpgroup.com (mailto:benchmark@mhpgroup.com)
About Benchmark
Benchmark is a market leading aquaculture biotechnology company. Benchmark's
mission is to drive sustainability in aquaculture by delivering products and
solutions in genetics, advanced nutrition and health which improve yield,
growth and animal health and welfare.
Through a global footprint in 26 countries and a broad portfolio of products
and solutions, Benchmark addresses many of the major aquaculture species -
salmon, shrimp, sea bass and sea bream, and tilapia - in all the major
aquaculture regions around the world. Find out more at www.benchmarkplc.com
Management Report
The Group delivered excellent performance in the first three months of the
year translating into a 36% growth in revenue and 61% growth in Adjusted
EBITDA excluding fair value movements from biological assets. Performance was
good across all business areas, with each business area reporting improved
revenues and Adjusted EBITDA excluding fair value movements from biological
assets when compared to the same period last year. On a constant exchange rate
basis, Group revenue and Adjusted EBITDA excluding fair value movements were
up 29% and 56% respectively.
Other operating costs were £11.8m, a 18% increase from the prior year (Q1
FY22: £9.9m) due to cost inflation and the impact of forex movements. By
business area, operating costs increased more significantly in Genetics
reflecting the investment in growth vectors including SPR shrimp, tilapia and
salmon in Chile. R&D expenses for the Group of £1.6m were in line with
the prior year. Total R&D investment including capitalised development
costs was £1.6m (Q1 FY22: £2.3m), reflecting commercialisation of SPR shrimp
during the previous year for which costs are no longer capitalised.
Adjusted EBITDA (excluding fair value movement from biological assets) was
£12.1m (Q1 FY22: £7.5m) driven by higher revenues, increased asset
utilisation and ongoing cost control. As a result, the Group achieved an
Adjusted EBITDA margin (excluding fair value movement from biological assets)
of 22% (Q1 FY22: 19%). Depreciation and amortisation increased 13% from the
comparative period last year to £10.1m (Q1 FY22: £8.9m) as a result of
investment in the businesses and £0.5m impairment of intangible assets in the
Health business area which are no longer being utilised. Exceptional costs
incurred in the period of £1.0m (Q1 FY22: £nil) related to costs associated
with the listing on Euronext Growth Oslo and preparation for up-listing on the
Oslo stock exchange. However, despite these increased costs, the Group
reported only a small operating loss of £0.1m, a significant improvement from
the £1.5m loss in Q1 FY22.
Net finance income in the period was £0.2m (Q1 FY22: £2.2m expense), with a
£2.5m credit relating to the ineffectively hedged portion of the movement in
the fair value of derivate instruments and a lower amortisation charge on
capitalised borrowing fees of £0.1m (Q1 FY22: £0.3m charge) offsetting the
increased interest charges (-£0.3m) following the refinancing exercise.
The Group reported a small profit before tax of £0.1m (Q1 FY22: loss before
tax £3.7m); the loss after tax for the period was £0.7m (Q1 FY22: loss after
tax £5.1m).
The Group's improved result translated in a significantly higher net operating
cash inflow from operating activities for the period at £8.1m (Q1 FY22:
inflow £1.1m). This was after an increase in working capital of £0.8m and
tax payments of £1.5m in the period. Net cash used in investing activities
was £2.2m (Q1 FY22: £2.6m) of which capex was £1.9m (Q1 FY22: £2.5m).
Capex in the period related to investment in Genetics (£1.3m), Nutrition
(£0.4m) and in Health (£0.2m). Net cash inflow from financing activities
was £2.2m, with net proceeds from the fundraise in December 2022 of £11.6m
being offset by £4.4m repayment of debt, £0.6m of capitalised borrowing
fees, £2.2m of interest paid and £2.2m of lease payments. Net increase in
cash in the quarter was £8.1m to leave the period end cash position at
£42.8m and liquidity of £62.8m.
Advanced Nutrition
Advanced Nutrition revenues were £22.7m, up 19% with sales higher in all
product areas, also aided by favourable forex rates in the period (revenues
increased at CER by 4%). By product area, sales of Artemia were +23%, Diets
+10% and Health +27% higher than Q1 FY22. Q1 FY23 Adjusted EBITDA was
£5.3m, up by 23% reflecting improved asset utilisation and ongoing cost
discipline. Adjusted EBITDA margin was consistent at 23% (Q1 FY22: 23%).
Notably, the Company's good performance in Advanced Nutrition was delivered
against a backdrop of soft market conditions entering into FY23 affected by
weather conditions in Thailand, the presence of SHIV virus in Indonesia and in
Latin America by high fuel costs combined with low farm gate prices.
Our continued growth in Advanced Nutrition revenues is a reflection of our
focused commercial effort which brings together our market leading, high
performing product portfolio, experienced technical support and a quality
oriented, reliable supply chain. We continue to innovate both in our existing
range and development of new products and during the period we carried out a
pre-launch of our Artemia counter, adding to our suite of Artemia technologies
to improve customer experience. Examples of our customer-centric commercial
effort in the period include trials of our specialist diets conducted by our
global and regional technical experts working together to optimise customer
performance in Indonesia, and artemia workshops conducted by our regional
technical support and local sales teams aimed at tailoring the use of artemia
tools and hatching protocols to individual customer needs.
Genetics
Genetics delivered revenues of £21.4m in Q1 FY23 (Q1 FY22: £15.2m),
reflecting a strong growth of 41% (+42% CER). This was driven primarily by
sales of salmon eggs and harvest income which increased by 57% and 31%,
respectively. Revenues from genetic services, our consulting business were 14%
ahead of Q1 FY22. There was a slowdown in the commercial roll-out of the SPR
shrimp as we refine our product offering based on customer feedback in our
first year of trading. As a result, sales from SPR shrimp were 20% below the
prior year.
Adjusted EBITDA for Q1 FY23 (excluding fair value movements of biological
assets) was £3.7m, 11% ahead of the prior year (Q1 FY22: £3.4m), and at
constant exchange rates, was 19% higher than the prior year. The fair value
movements on biological assets in the quarter was a £1.1m reduction in value
(Q1 FY22: £0.1m reduction), so Adjusted EBITDA including fair value movements
for Q1 FY23 was £2.6m (Q1 FY22: £3.3m).
Post period end the Company announced the retirement of Jan-Emil Johannessen,
Head of Benchmark Genetics who will be succeeded by Geir Olav Melingen,
currently Commercial Director Salmon at Benchmark, with effect from 1 June
2023. During his tenure Jan-Emil has built a talented and experienced team
capable of taking Benchmark Genetics through the next phase of growth. Geir
Olav Melingen has extensive experience from leading roles in the aquaculture
industry including at MSD, as CEO of Fishguard and CEO of the Bergen Aquarium.
He has deep experience in fish health and the salmon industry with a PhD in
fish health from the University of Bergen.
Health
Revenues in Q1 FY23 were £10.4m (Q1 FY22: £5.8m) as a result of
significantly increased customer uptake and sales of Ectosan® Vet and
CleanTreat® and significant growth in Salmosan Vet - our well established sea
lice treatment. Revenues from Ectosan® Vet and CleanTreat® were £7.5m of
which £1.7m was derived from recharging vessel and fuel costs associated with
the Ectosan® Vet and CleanTreat® operations.
Revenues from Salmosan® Vet, our long-established sea lice treatment were
£2.9m (Q1 FY22: £1.3m) with significant growth achieved in Canada, Norway
and the Faroe Islands. Growth was driven by a variation to the marketing label
which supports a longer product exposure, as well as enhanced engagement with
customers through our portfolio of sea lice solutions which can be used in
combination to address our customers' sea lice challenge.
The significant increase in revenues resulted in Adjusted EBITDA of £4.1m in
the quarter (Q1 FY22: £0.5m) demonstrating the potential of this business
area to deliver good profitability.
Operationally we continue to make improvements in the efficiency of the
delivery of our Ectosan® Vet and CleanTreat® solution achieving a new record
in the speed of water transfer between the treatment wellboat and the
CleanTreat® units, a key parameter for our customers. Speed of water transfer
is now approximately double what it was at launch.
In the period we made progress towards a new business model for Ectosan® Vet
and CleanTreat® aimed at lowering the Company's exposure to infrastructure
costs by lowering capital intensity and capital investment. The Company has
established a partnership with leading specialist wellboat equipment provider
MMC and ship designer SALT to capture opportunities to integrate its
CleanTreat® systems into new wellboats coming to the market. The speed of
adoption of a fully integrated solution on wellboats is reliant on the
availability and customer adoption of new large wellboats. Customer owned
PSV's/platforms are a viable alternative to large wellboats in the medium to
long term.
Oslo Børs uplisting and delisting from AIM
As previously announced at the end of FY22, the Company intends to up-list
from Euronext Growth Oslo to the Oslo Børs and we are making progress towards
this goal. Oslo is the leading listing venue for aquaculture and seafood
companies. There are 27 listed companies in the seafood sector in Oslo while
Benchmark is the only pure play aquaculture company listed on the London Stock
Exchange. A listing on the Oslo Børs provides natural access to an
important pool of specialist investors best equipped to recognise the
Company's added value and growth potential. The Company is conducting a
consultation with shareholders on whether to maintain a listing on AIM. The
potential up-listing to the Oslo Børs and delisting from AIM are subject to
shareholder approval and market conditions.
Current Trading and Outlook
Post period end the Company continues to perform well across all business
areas and the outlook for the full year is encouraging. This reflects good
visibility of revenues in Genetics, a positive performance in Advanced
Nutrition despite soft shrimp markets, and increasing evidence of customer
adoption for Ectosan® Vet and CleanTreat® in Health.
Benchmark Holdings plc
Consolidated Income Statement for the period ended 31 December 2022
All figures in £000's Notes Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Revenue 4 54,495 40,014 158,277
Cost of sales (30,268) (20,515) (75,149)
Gross profit 24,227 19,499 83,128
Research and development costs (1,563) (1,647) (6,691)
Other operating costs (11,753) (9,923) (44,661)
Share of profit/(loss) of equity-accounted investees, net of tax 56 (504) (595)
Adjusted EBITDA² 10,967 7,425 31,181
Exceptional items 5 (972) - 16
EBITDA¹ 9,995 7,425 31,197
Depreciation and impairment (4,615) (4,495) (19,897)
Amortisation and impairment (5,502) (4,388) (19,161)
Operating loss (122) (1,458) (7,861)
Finance cost (7,286) (2,343) (20,057)
Finance income 7,508 119 4,741
Profit/(loss) before taxation 100 (3,682) (23,177)
Tax on loss 6 (779) (1,427) (7,274)
Loss for the period (679) (5,109) (30,451)
Loss for the period attributable to:
- Owners of the parent (1,283) (5,357) (32,087)
- Non-controlling interest 604 248 1,636
(679) (5,109) (30,451)
Earnings per share
Basic loss per share (pence) 7 (0.18) (0.79) (4.60)
Diluted loss per share (pence) 7 (0.18) (0.79) (4.60)
1 EBITDA - Earnings before interest, tax, depreciation, amortisation, and
impairment
2 Adjusted EBITDA - EBITDA before exceptional items
Benchmark Holdings plc
Consolidated Statement of Comprehensive Income for the period ended 31
December 2022
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Loss for the period (679) (5,109) (30,451)
Other comprehensive income
Items that are or may be reclassified subsequently to profit or loss
Foreign exchange translation differences (18,040) (2,611) 47,606
Cash flow hedges - changes in fair value (516) (134) 2,627
Cash flow hedges - reclassified to profit or loss (113) 115 2,546
Total comprehensive income for the period (19,348) (7,739) 22,328
Total comprehensive income for the period attributable to:
- Owners of the parent (19,751) (7,948) 20,326
- Non-controlling interest 403 209 2,002
(19,348) (7,739) 22,328
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Balance Sheet as at 31 December 2022
31 December 2022 31 December 2021 30 September 2022
All figures in £000's Notes (unaudited) (unaudited) (audited)
Assets
Property, plant and equipment 80,505 78,082 81,900
Right-of-use assets 23,883 23,062 27,034
Intangible assets 224,606 224,192 245,264
Equity-accounted investees 3,041 2,815 3,113
Other investments 15 15 15
Biological and agricultural assets 24,930 21,206 20,878
Trade and other receivables 422 - -
Non-current assets 357,402 349,372 378,204
Inventories 28,222 21,343 29,813
Biological and agricultural assets 17,154 17,137 25,780
Trade and other receivables 51,159 43,267 56,377
Cash and cash equivalents 42,782 52,705 36,399
Current assets 139,317 134,452 148,369
Total assets 496,719 483,824 526,573
Liabilities
Trade and other payables (35,254) (39,001) (44,324)
Loans and borrowings 8 (16,227) (6,872) (17,091)
Corporation tax liability (10,349) (6,936) (10,211)
Provisions (1,587) (557) (1,631)
Current liabilities (63,417) (53,366) (73,257)
Loans and borrowings 8 (87,958) (110,119) (93,045)
Other payables (4,369) (895) (8,996)
Deferred tax (25,105) (27,159) (27,990)
Non-current liabilities (117,432) (138,173) (130,031)
Total liabilities (180,849) (191,539) (203,288)
Net assets 315,870 292,285 323,285
Issued capital and reserves attributable to owners of the parent
Share capital 9 739 704 704
Additional paid-in share capital 9 432,423 420,754 420,824
Capital redemption reserve 5 5 5
Retained earnings (186,120) (159,269) (185,136)
Hedging reserve (1,332) (5,895) (703)
Foreign exchange reserve 59,866 27,893 77,705
Equity attributable to owners of the parent 305,581 284,192 313,399
Non-controlling interest 10,289 8,093 9,886
Total equity and reserves 315,870 292,285 323,285
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Statement of Changes in Equity for the period ended 31 December
2022
Share Additional paid-in share capital* Other Hedging Retained Total attributable Non- Total
capital
reserves
reserve
earnings
to equity holders of
controlling
equity
parent
interest
£000 £000 £000 £000 £000 £000 £000 £000
As at 1 October 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
Comprehensive income for the period
(Loss)/profit for the period - - - - (1,283) (1,283) 604 (679)
Other comprehensive income - - (17,839) (629) - (18,468) (201) (18,669)
Total comprehensive income for the period - - (17,839) (629) (1,283) (19,751) 403 (19,348)
Contributions by and distributions to owners
Share issue 35 12,985 - - - 13,020 - 13,020
Share issue costs recognised through equity - (1,386) - - - (1,386) - (1,386)
Share-based payment - - - - 299 299 - 299
Total contributions by and distributions to owners 35 11,599 - - 299 11,933 - 11,933
Total transactions with owners of the Company 35 11,599 - - 299 11,933 - 11,933
As at 31 December 2022 (unaudited) 739 432,423 59,871 (1,332) (186,120) 305,581 10,289 315,870
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income for the period
(Loss)/profit for the period - - - - (5,357) (5,357) 248 (5,109)
Other comprehensive income - - (2,572) (19) - (2,591) (39) (2,630)
Total comprehensive income for the period - - (2,572) (19) (5,357) (7,948) 209 (7,739)
Contributions by and distributions to owners
Share issue 34 20,634 - - - 20,668 - 20,668
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 319 319 - 319
Total contributions by and distributions to owners 34 20,072 - - 319 20,425 - 20,425
Total transactions with owners of the Company 34 20,072 - - 319 20,425 - 20,425
As at 31 December 2021 (unaudited) 704 420,754 27,898 (5,895) (159,269) 284,192 8,093 292,285
As at 1 October 2021 (audited) 670 400,682 30,470 (5,876) (154,231) 271,715 7,884 279,599
Comprehensive income for the period
(Loss)/profit for the period - - - - (32,087) (32,087) 1,636 (30,451)
Other comprehensive income - - 47,240 5,173 - 52,413 366 52,779
Total comprehensive income for the period - - 47,240 5,173 (32,087) 20,326 2,002 22,328
Contributions by and distributions to owners
Share issue 34 20,704 - - - 20,738 - 20,738
Share issue costs recognised through equity - (562) - - - (562) - (562)
Share-based payment - - - - 1,182 1,182 - 1,182
Total contributions by and distributions to owners 34 20,142 - - 1,182 21,358 - 21,358
Total transactions with owners of the Company 34 20,142 - - 1,182 21,358 - 21,358
As at 30 September 2022 (audited) 704 420,824 77,710 (703) (185,136) 313,399 9,886 323,285
*Other reserves in this statement is an aggregation of capital redemption
reserve and foreign exchange reserve.
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Consolidated Statement of Cash Flows for the period ended 31 December 2022
Q1 2023 (unaudited) Q1 2022 (unaudited) FY 2022 (audited)
£000 £000 £000
Cash flows from operating activities
Loss for the period (679) (5,109) (30,451)
Adjustments for:
Depreciation and impairment of property, plant and equipment 2,033 2,022 8,602
Depreciation and impairment of right-of-use assets 2,582 2,473 11,295
Amortisation and impairment of intangible fixed assets 5,502 4,388 19,161
Loss on sale of property, plant and equipment (37) - (43)
Finance income (7,508) (119) (319)
Finance costs 7,010 2,247 18,437
Increase in fair value of contingent consideration receivable - - (1,203)
Share of (profit)/loss of equity-accounted investees, net of tax (56) 504 595
Foreign exchange losses/(gains) 418 (9) (3,985)
Share-based payment expense 299 319 1,182
Other adjustments for non-cash items - - (276)
Tax charge 779 1,427 7,274
Decrease/(increase) in trade and other receivables 4,011 2,683 (8,511)
Decrease/(increase) in inventories 1,571 (880) (5,406)
Decrease/(increase) in biological and agricultural assets 3,294 (138) (6,099)
(Decrease)/increase in trade and other payables (9,633) (7,687) 6,946
(Decrease)/increase in provisions (9) (6) 1,058
9,577 2,115 18,257
Income taxes paid (1,509) (981) (7,447)
Net cash flows generated from operating activities 8,068 1,134 10,810
Investing activities
Purchase of investments (63) - (378)
Receipts from disposal of investments - - 1,544
Purchases of property, plant and equipment (1,829) (1,914) (10,808)
Purchase of intangibles (30) (53) (205)
Capitalised research and development costs (54) (627) (1,708)
Cash advances and loans made to other parties (415) - -
Proceeds from sale of fixed assets 75 - 220
Interest received 160 19 119
Net cash flows used in investing activities (2,156) (2,575) (11,216)
Financing activities
Proceeds of share issues 13,020 20,712 20,737
Share-issue costs recognised through equity (1,386) (607) (562)
Proceeds from bank or other borrowings - - 67,939
Repayment of bank or other borrowings (4,397) (638) (74,874)
Interest and finance charges paid (2,211) (1,882) (9,629)
Capitalised borrowing costs (600) - -
Repayments of lease liabilities (2,200) (2,730) (10,533)
Net cash inflow/(outflow) from financing activities 2,226 14,855 (6,922)
Net increase/(decrease) in cash and cash equivalents 8,138 13,414 (7,328)
Cash and cash equivalents at beginning of period 36,399 39,460 39,460
Effect of movements in exchange rate (1,755) (169) 4,267
Cash and cash equivalents at end of period 42,782 52,705 36,399
The accompanying notes are an integral part of this consolidated financial
information.
Benchmark Holdings plc
Unaudited notes to the quarterly financial statements for the period ended 31
December 2022
1. Basis of preparation
Benchmark Holdings plc (the 'Company') is a company incorporated and domiciled
in the United Kingdom. These consolidated quarterly financial statements as at
and for the three months ended 31 December 2022 comprises those of the Company
and its subsidiaries (together referred to as the 'Group').
These consolidated quarterly financial statements do not comprise statutory
accounts within the meaning of section 434 of the Companies Act 2006 and are
unaudited. These financial statements do not include all the information
required for a complete set of IFRS financial statements. However, selected
explanatory notes are included to explain events and transactions that are
significant to an understanding of the changes in the Group's financial
position and performance since the last annual financial statements. The
Group's last annual statutory financial statements as at and for the year
ended 30 September 2022 were prepared in accordance with UK adopted
international accounting standards in conformity with the requirements of the
Companies Act 2006 as it applies to companies reporting under those standards
("Adopted IFRS") and are available from the Company's website at
www.benchmarkplc.com (http://www.benchmarkplc.com) .
The prior year comparatives are derived from audited financial information for
Benchmark Holdings PLC Group as set out in the Annual Report and Accounts for
the year ended 30 September 2022 and the unaudited financial information in
the Quarterly Financial Report for the three months ended 31 December 2021.
The comparative figures for the financial year ended 30 September 2022 are
not the Company's statutory accounts for that financial year. Those accounts
were approved by the Directors on 30 November 2022 and have been delivered to
the Registrar of Companies. The audit report received on those accounts was
(i) unqualified and (ii) did not include a reference to any matters to which
the external auditor drew attention by way of emphasis without qualifying
their report, and (iii) did not contain a statement under section 498(2) or
(3) of the Companies Act 2006.
Statement of Compliance
These consolidated quarterly financial statements have been prepared in
accordance with UK and EU adopted IAS 34 'Interim Financial Reporting'. These
financial statements do not include all of the information required for the
full annual financial statements and should be read in conjunction with the
Group's last annual consolidated financial statements as at and for the year
ended 30 September 2022. These consolidated quarterly financial statements
were approved by the Board of Directors on 28 February 2022.
Going concern
The Group's business activities, together with the factors likely to affect
its future development, performance and position are set out in the Management
Report.
As at 31 December 2022 the Group had net assets of £315.9m (30 September
2022: £323.3m), including cash of £42.8m (30 September 2022: £36.4m) as
set out in the consolidated balance sheet. The Group made a loss for the
period of £0.7m (year ended 30 September 2022: loss £30.5m).
As noted in the Management Report, the business has continued to perform well
on the back of a good year in FY22. All of the business areas have performed
in line with or ahead of management expectations. The Directors have
reviewed forecasts and cash flow projections for a period of at least 12
months including downside sensitivity assumptions in relation to trading
performance across the Group to assess the impact on the Group's trading and
cash flow forecasts and on the forecast compliance with the covenants included
within the Group's financing arrangements.
In the downside analysis performed, the Directors considered severe but
plausible scenarios on the Group's trading and cash flow forecasts, firstly in
relation to continued roll out of the Ectosan®Vet and CleanTreat offering.
Sensitivities considered included modelling slower ramp up of the
commercialisation of Ectosan® Vet and CleanTreat® through delayed roll-out
of the revised operating model for the service, together with reductions in
expected biomass treated and reduced treatment prices. Key downside
sensitivities modelled in other areas included assumptions on slower
commercialisation of SPR shrimp, slower salmon egg sales growth both in Chile
and to land-based farms in Genetics, along with sensitivities on sales price
increases and potential supply constraints on CIS artemia in Advanced
Nutrition. Mitigating measures within the control of management have been
identified should they be required in response to these sensitivities,
including reductions in areas of discretionary spend, deferral of capital
projects and temporary hold on R&D for non-imminent products.
Following the refinancing of its NOK 850 million bond with the issue of a NOK
750 million unsecured green bond maturing in 2025 in FY22, which was due to
mature in June 2023, the USD15m RCF was refinanced in the quarter with a new
GBP20m RCF with a maturity of June 2025. Also in the quarter, our NOK 216m
loan facility (which had NOK 165.6m outstanding at the year end) which was set
to mature in October 2023, was combined with our NOK 17.5m overdraft facility
into a new loan facility of NOK 179.5m, with a new maturity date in a further
5 years no later than 15 January 2028. Following all of these refinancing
transactions, the Directors are satisfied there are sufficient facilities in
place during the assessment period.
The global economic environment is experiencing turbulence largely as a result
of the conflict in Eastern Europe with supply issues in a number of industries
impacted and inflation at high levels. Against this backdrop, the Group
continues to show resilience against these pressures, with financial
instruments in place to fix interest rates and with opportunities available to
mitigate globally high inflation rates, such that even under all of the above
sensitivity analysis, the Group has sufficient liquidity and resources
throughout the period under review whilst still maintaining adequate headroom
against the borrowing covenants.
The Directors therefore remain confident that the Group has adequate resources
to continue to meet its liabilities as and when they fall due within the
period of 12 months from the date of approval of these financial statements.
Based on their assessment, the Directors believe it remains appropriate to
prepare the financial statements on a going concern basis.
2. Accounting policies
The accounting policies adopted are consistent with those used in preparing
the consolidated financial statements for the financial year ended 30
September 2022.
Taxes on income in the interim periods are accrued using the tax rate that
would be applicable to expected total earnings.
Alternative performance measures ('APMs')
The Directors measure the performance of the Group based on a range of
financial measures, including measures not recognised by EU-adopted IFRS.
These APMs may not be directly comparable with other companies' APMs, and the
Directors do not intend these as a substitute for, or superior to, IFRS
measures.
Directors have presented the performance measures Adjusted EBITDA, Adjusted
Operating Profit, Adjusted Profit Before Tax and Adjusted EBITDA excluding
fair value movement on biological assets because they monitor performance at a
consolidated level using these and believe that these measures are relevant to
an understanding of the Group's financial performance (see note 10).
Furthermore, the Directors also refer to current period results using constant
currency, which are derived by retranslating current period results using the
prior year's foreign exchange rates.
Use of estimates and judgements
The preparation of quarterly financial information requires management to make
certain judgements, estimates and assumptions that affect the application of
accounting policies and the reported amounts of assets and liabilities, income
and expense. Actual amounts may differ from these estimates.
In preparing these quarterly financial statements the critical judgements made
by management in applying the Group's accounting policies and the key sources
of estimation uncertainty were the same as those applied to the consolidated
financial statements for the year ended 30 September 2022.
3. Segment information
Operating segments are reported in a manner consistent with the reports made
to the chief operating decision maker. It is considered that the role of chief
operating decision maker is performed by the Board of Directors.
The Group operates globally and for management purposes is organised into
reportable segments based on the following business areas:
· Genetics - harnesses industry leading salmon breeding
technologies combined with state-of-the-art production facilities to provide a
range of year-round high genetic merit ova and technical services.
· Advanced Nutrition - manufactures and provides technically
advanced nutrition and health products to the global aquaculture industry.
· Health -provides health products and services to the global
aquaculture market.
In order to reconcile the segmental analysis to the consolidated income
statement, corporate and inter-segment sales are also shown. Corporate sales
represent revenues earned from recharging certain central costs to the
operating business areas, together with unallocated central costs.
Measurement of operating segment profit or loss
Inter-segment sales are priced along the same lines as sales to external
customers, with an appropriate discount being applied to encourage use of
Group resources at a rate acceptable to local tax authorities. This policy
was applied consistently throughout the current and prior period.
Reconciliations of segmental information to IFRS measures
Segmental Revenue
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Genetics 21,439 15,195 58,008
Advanced Nutrition 22,680 19,059 80,286
Health 10,385 5,777 20,135
Corporate 1,437 1,406 5,120
Inter-segment sales (1,446) (1,423) (5,272)
Total 54,495 40,014 158,277
Segmental Adjusted EBITDA
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Genetics 2,563 3,263 15,980
Advanced Nutrition 5,297 4,320 19,017
Health 4,067 547 108
Corporate (960) (705) (3,924)
Total 10,967 7,425 31,181
Reconciliation of Reportable Segments Adjusted EBITDA to Loss before
taxation
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Total reportable segment Adjusted EBITDA 11,927 8,130 35,105
Corporate Adjusted EBITDA (960) (705) (3,924)
Adjusted EBITDA 10,967 7,425 31,181
Exceptional items (972) - 16
Depreciation and impairment (4,615) (4,495) (19,897)
Amortisation and impairment (5,502) (4,388) (19,161)
Net finance income/(costs) 222 (2,224) (15,316)
Profit/(loss) before taxation 100 (3,682) (23,177)
4. Revenue
The Group's operations and main revenue streams are those described in its
financial statements to 30 September 2022. The Group's revenue is derived from
contracts with customers.
Disaggregation of revenue
In the following tables, revenue is disaggregated by primary geographical
market and by sales of goods and services. The table includes a reconciliation
of the disaggregated revenue with the Group's reportable segments (see note
3).
Sale of goods and provision of services
3 months ended 31 December 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 21,121 22,672 7,449 - - 51,242
Provision of services 317 - 2,936 - - 3,253
Inter-segment sales 1 8 - 1,437 (1,446) -
21,439 22,680 10,385 1,437 (1,446) 54,495
3 months ended 31 December 2021 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 14,509 19,048 3,251 - - 36,808
Provision of services 680 - 2,526 - - 3,206
Inter-segment sales 6 11 - 1,406 (1,423) -
15,195 19,059 5,777 1,406 (1,423) 40,014
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Sale of goods 53,978 80,191 13,528 - - 147,697
Provision of services 3,973 - 6,607 - - 10,580
Inter-segment sales 57 95 - 5,120 (5,272) -
58,008 80,286 20,135 5,120 (5,272) 158,277
Sale of goods and provision of services (continued)
Primary geographical markets
3 months ended 31 December 2022 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 16,884 90 8,295 - - 25,269
India - 4,203 - - - 4,203
Singapore - 39 - - - 39
Turkey 6 2,204 - - - 2,210
Ecuador 20 1,740 - - - 1,760
Greece - 2,269 - - - 2,269
Faroe Islands 1,095 - 229 - - 1,324
UK 737 19 42 - - 798
Chile 12 2 254 - - 268
Rest of Europe 2,062 1,622 - - - 3,684
Rest of World 622 10,484 1,565 - - 12,671
Inter-segment sales 1 8 - 1,437 (1,446) -
21,439 22,680 10,385 1,437 (1,446) 54,495
3 months ended 31 December 2021 (unaudited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 9,679 112 4,668 - - 14,459
India 140 4,008 - - - 4,148
Singapore - 1,138 - - - 1,138
Turkey - 1,694 - - - 1,694
Ecuador - 1,064 - - - 1,064
Greece - 1,639 - - - 1,639
Faroe Islands 892 1 130 - - 1,023
UK 1,957 14 88 - - 2,059
Chile 116 - 403 - - 519
Rest of Europe 1,771 1,303 - - - 3,074
Rest of World 634 8,075 488 - - 9,197
Inter-segment sales 6 11 - 1,406 (1,423) -
15,195 19,059 5,777 1,406 (1,423) 40,014
Primary geographical markets (continued)
12 months ended 30 September 2022 (audited)
All figures in £000's Genetics Advanced Nutrition Health Corporate Inter-segment sales Total
Norway 34,666 965 15,571 - - 51,202
India 619 12,001 - - - 12,620
Singapore - 7,044 - - - 7,044
Turkey - 6,419 - - - 6,419
Ecuador 18 6,472 - - - 6,490
Greece 2 6,197 - - - 6,199
Faroe Islands 5,465 9 587 - - 6,061
UK 4,318 93 199 - - 4,610
Chile 1,006 15 871 - - 1,892
Rest of Europe 7,110 4,056 - - - 11,166
Rest of World 4,747 36,920 2,907 - - 44,574
Inter-segment sales 57 95 - 5,120 (5,272) -
58,008 80,286 20,135 5,120 (5,272) 158,277
5. Exceptional items
Items that are material because of their size or nature, non-recurring and
whose significance is sufficient to warrant separate disclosure and
identification within the consolidated financial statements are referred to as
exceptional items. The separate reporting of exceptional items helps to
provide an understanding of the Group's underlying performance.
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Exceptional restructuring costs 948 - 1,229
Costs/(credit) in relation to disposals 24 - (1,245)
Total exceptional items 972 - (16)
Exceptional restructuring costs include £863,000 of legal and professional
costs in relation to preparing for listing the Group on the Oslo stock
exchange, and £85,000 relating to other restructuring costs. The comparative
figure for FY 2022 figure includes £843,000 of legal and professional costs
in relation to preparing for listing the Group on the Oslo stock exchange, and
£276,000 relating to other restructuring costs.
Costs in relation to disposals totaling £24,000 are additional costs relating
to disposals that occurred in 2020. The comparative figure for FY 2022 figure
includes a credit of £1,203,000 in relation to additional contingent
consideration received and receivable from disposals in previous years
(£294,000 relating to the disposal of Aquaculture UK on 7 February 2020, and
£909,000 relating to the disposal of Improve International Limited and its
subsidiaries on 23 June 2020) together with legal fees, lease costs and
disposal items (net of proceeds received) totalling £42,000 relating to
additional costs and disposals proceeds relating to disposals that occurred in
2020.
6. Taxation
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Analysis of charge in period
Current tax:
Current income tax expense on profits for the period 1,838 2,359 11,727
Adjustment in respect of prior periods - 5 (39)
Total current tax charge 1,838 2,364 11,688
Deferred tax:
Origination and reversal of temporary differences (1,059) (937) (4,414)
Deferred tax movements in respect of prior periods - - -
Total deferred tax credit (1,059) (937) (4,414)
-
Total tax charge 779 1,427 7,274
7. Loss per share
Basic loss per share is calculated by dividing the loss attributable to
ordinary equity holders of the Company by the weighted average number of
ordinary shares in issue during the period.
Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Loss attributable to equity holders of the parent (£000) (1,283) (5,357) (32,087)
Weighted average number of shares in issue (thousands) 710,087 681,271 698,233
Basic loss per share (pence) (0.18) (0.79) (4.60)
Diluted loss per share is calculated by adjusting the weighted average number
of ordinary shares outstanding to assume conversion of all dilutive potential
ordinary shares. This is done by calculating the number of shares that could
have been acquired at fair value (determined as the average market price of
the Company's shares for the period) based on the monetary value of the
subscription rights attached to outstanding share options and warrants. The
number of shares calculated above is compared with the number of shares that
would have been issued assuming the exercise of the share options and
warrants.
Therefore, the Company is required to adjust the earnings per share
calculation in relation to the share options that are in issue under the
Company's share-based incentive schemes, and outstanding warrants. However, as
any potential ordinary shares would be anti-dilutive due to losses being made
there is no difference between Basic loss per share and Diluted loss per share
for any of the periods being reported.
A total of 4,053,469 potential ordinary shares have not been included within
the calculation of statutory diluted loss per share for the year (30 September
2022: 6,240,304 and 31 December 2021: 5,782,581). These potential ordinary
shares could dilute earnings/loss per share in the future.
8. Loans and borrowings
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Non-Current
2025 750m NOK Loan notes 61,866 - 61,054
2023 850m NOK Loan notes - 75,592 -
Bank borrowings 17,201 18,578 17,226
Lease liabilities 8,891 15,949 14,765
87,958 110,119 93,045
Current
Bank borrowings 1,603 1,592 5,569
Lease liabilities 14,624 5,280 11,522
16,227 6,872 17,091
Total loans and borrowings 104,185 116,991 110,136
On 27 September 2022, the Group successfully issued a new unsecured floating
rate listed green bond of NOK 750m. The bond which matures in September 2025,
has a coupon of three-month NIBOR + 6.50% p.a. with quarterly interest
payments, and is to be listed on the Oslo Stock Exchange. The proceeds were
used to repay its existing NOK 850m floating rate listed bond, originally
raised in June 2019.
On 21 November 2022, the Group refinanced its USD15m RCF, which was provided
by DNB Bank ASA (50%) and HSBC UK Bank PLC (50%), with a secured GBP20m RCF
provided by DNB Bank ASA, maturing on 27 June 2025. The margin on this
facility is a minimum of 2.75% and a maximum of 3.25%, dependent upon the
leverage of the Group above the relevant risk free reference or IBOR rates
depending on which currency is drawn. The facility was undrawn at 31
December 2022.
Additionally, during the period, on 1 November 2022, the Group's Nordea Bank
term loan of NOK 165.6m, which had a term loan of five years ending in
November 2023 and interest rate of 2.5% above three month NIBOR, was
refinanced together with an existing undrawn overdraft facility into a new
loan facility of NOK 179.5m with a new maturity date in a further five years
no later than 15 January 2028. Other terms of this facility remain the same.
9. Share capital and additional paid-in share capital
Number Share Capital Additional paid-in
share capital
Allotted, called up and fully paid £000 £000
Ordinary shares of 0.1 pence each
Balance at 30 September 2022 703,960,798 704 420,824
Shares issued through placing and open offer 35,189,350 35 11,599
Exercise of share options 45,000 - -
Balance at 31 December 2022 739,195,148 739 432,423
On 15 December 2022, the Company issued 35,189,350 new ordinary shares of 0.1
pence each by way of a placing and subscriptions at an issue price of 37.0
pence per share. Gross proceeds of £13.0m were received for the placing and
subscription shares. Non-recurring costs of £1.4m were in relation to the
share issues and this has been charged to the share premium account (presented
within additional paid-in share capital).
10. Alternative performance measures and other metrics
Management has presented the performance measures EBITDA, Adjusted EBITDA,
Adjusted EBITDA before fair value movement in biological assets, Adjusted
Operating Profit and Adjusted Profit Before Tax because it monitors
performance at a consolidated level using these and believes that these
measures are relevant to an understanding of the Group's financial
performance.
Adjusted EBITDA which reflects underlying profitability, is earnings before
interest, tax, depreciation, amortisation, impairment, and exceptional items
and is shown on the Income Statement.
Adjusted EBITDA before fair value movements in biological assets, which is
Adjusted EBITDA before the non-cash fair value movements in biological assets
arising from their revaluation in line with International Accounting
Standards.
Adjusted Operating Profit is operating loss before exceptional items and
amortisation and impairment of intangible assets excluding development costs
as reconciled below.
Adjusted Profit Before Tax is earnings before tax, amortisation and impairment
of intangibles assets excluding development costs, and exceptional items as
reconciled below. These measures are not defined performance measures in IFRS.
The Group's definition of these measures may not be comparable with similarly
titled performance measures and disclosures by other entities.
Reconciliation of Adjusted Operating Profit to Operating Loss
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Revenue 54,495 40,014 158,277
Cost of sales (30,268) (20,515) (75,149)
Gross profit 24,227 19,499 83,128
Research and development costs (1,563) (1,647) (6,691)
Other operating costs (11,753) (9,923) (44,661)
Depreciation and impairment (4,615) (4,495) (19,897)
Amortisation of capitalised development costs (617) (448) (2,165)
Share of loss of equity accounted investees net of tax 56 (504) (595)
Adjusted operating profit 5,735 2,482 9,119
Exceptional items (972) - 16
Amortisation and impairment of intangible assets excluding development costs (4,885) (3,940) (16,996)
Operating loss (122) (1,458) (7,861)
Reconciliation of Loss Before Taxation to Adjusted Profit Before Tax
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Profit/(loss) before taxation 100 (3,682) (23,177)
Exceptional items 972 - (16)
Amortisation and impairment of intangible assets excluding development costs 4,885 3,940 16,996
Adjusted profit before tax 5,957 258 (6,197)
Other Metrics
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Total R&D Investment
Research and development costs 1,563 1,647 6,691
Internal capitalised development costs 54 627 1,708
Total R&D investment 1,617 2,274 8,399
All figures in £000's Q1 2023 Q1 2022 FY 2022
(unaudited)
(unaudited)
(audited)
Adjusted EBITDA excluding fair value movement in biological assets
Adjusted EBITDA 10,967 7,425 31,181
Exclude fair value movement 1,154 96 (1,595)
Adjusted EBITDA excluding fair value movement in biological assets 12,121 7,521 29,586
Liquidity
A key financial covenant is a minimum liquidity of £10m, defined as cash plus
undrawn facilities.
31 December 2022
All figures in £000's (unaudited)
Cash and cash equivalents 42,782
Undrawn bank facility 20,000
62,782
The undrawn bank facility relates to the RCF facility. At 31 December 2022,
£nil of the RCF was drawn (30 September 2022: £4m and 31 December 2021:
£nil), leaving £20m undrawn (30 September 2022: £9.4m and 31 December 2021:
£11.1m).
11. Net debt
Net debt is cash and cash equivalents less loans and borrowings.
31 December 2022 31 December 2021 30 September 2022
All figures in £000's (unaudited) (unaudited) (audited)
Cash and cash equivalents 42,782 52,705 36,399
Loans and borrowings (excluding lease liabilities) - current (1,603) (1,592) (5,569)
Loans and borrowings (excluding lease liabilities) - non-current (79,067) (94,170) (78,280)
Net debt excluding lease liabilities (37,888) (43,057) (47,450)
Lease liabilities - current (14,624) (5,280) (11,522)
Lease liabilities - non-current (8,891) (15,949) (14,765)
Net debt (61,403) (64,286) (73,737)
12. Post balance sheet events
On 15 February 2023, the Group purchased the minority interest's shareholding
of 14,981,272 shares in Benchmark Genetics Iceland HF for €9,000,000.
Following this acquisition, Benchmark Genetics Limited, a subsidiary of
Benchmark Holdings PLC, now owns 100% of the share capital of Benchmark
Genetics Iceland HF.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END QRFPPUQGPUPWUUR